SG3 Management’s Haemonetics HAE Stock Holding History

SG3 Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-6,000	Closed	-$524K	–	1094
2020 Q3	$524K	Buy	+6,000	New	+$524K	0.02%	557

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SG3 Management's HAE Position: Q4 2020 in Review

SG3 Management sold out of Haemonetics (HAE) in Q4 2020, closing a stake of 6,000 shares — an estimated $524K sold.

SG3 Management first reported a position in HAE in Q3 2020 and held it in 1 quarter. The position peaked at $524K in Q3 2020. 286 funds tracked by Wall St. Rank hold HAE as of Q4 2020.

SG3 Management reported no remaining Haemonetics position as of Q4 2020 after selling out during the quarter.
SG3 Management sold 6,000 Haemonetics shares in Q4 2020, an estimated $524K.
SG3 Management first reported a position in Haemonetics in Q3 2020 and held it in 1 quarter.
SG3 Management's Haemonetics position peaked at $524K in Q3 2020.
286 funds tracked by Wall St. Rank held Haemonetics as of Q4 2020.

Based on SG3 Management's 13F filing for Q4 2020, filed 16 Feb 2021.